Bpi Drug Patent Portfolio
Bpi owns 1 orange book drug protected by 3 US patents Given below is the list of Bpi's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9283197 | More potent and less toxic formulations of epinephrine and methods of medical use | 15 Aug, 2034 | Active |
| US10004700 | More potent and less toxic formulations of epinephrine and methods of medical use | 14 Aug, 2034 | Active |
| US10039728 | More potent and less toxic formulations of epinephrine and methods of medical use | 14 Aug, 2034 | Active |
Latest Legal Activities on Bpi's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Bpi.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Pubs Case Remand to TC | 22 Dec, 2025 | US12539283 |
| Email Notification | 11 Dec, 2025 | US12539283 |
| Workflow - Request for RCE - Finish | 10 Dec, 2025 | US12539283 |
| Petition Entered | 10 Dec, 2025 | US12539283 |
| Issue Notification Mailed | 10 Dec, 2025 | US12539283 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 10 Dec, 2025 | US10004700 |
| IDS with certification statement | 10 Dec, 2025 | US12539283 |
| Quick Path IDS Request | 10 Dec, 2025 | US12539283 |
| Information Disclosure Statement (IDS) Filed | 10 Dec, 2025 | US12539283 |
| Mail-Record Petition Decision of Granted to Withdraw from Issue - with assigned Patent NO. | 10 Dec, 2025 | US12539283 |
| Record Petition Decision of Granted to Withdraw from Issue - with assigned Patent NO. | 10 Dec, 2025 | US12539283 |
| Workflow - Request for RCE - Begin | 10 Dec, 2025 | US12539283 |
| Withdrawal Patent Case from Issue | 10 Dec, 2025 | US12539283 |
| Application Is Considered Ready for Issue | 25 Nov, 2025 | US12539283 |
| Dispatch to FDC | 25 Nov, 2025 | US12539283 |
Bpi's Drug Patent Litigations
Bpi's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Apr 26, 2019, against patent number US9283197. The petitioner Adamis Pharmaceuticals Corporation, challenged the validity of this patent, with Belcher Pharmaceuticals, LLC as the respondent. Click below to track the latest information on how companies are challenging Bpi's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US9283197 | April, 2019 |
Terminated-Settled
(02 Aug, 2019)
| Belcher Pharmaceuticals, LLC | Adamis Pharmaceuticals Corporation |
Bpi's Family Patents
Recent FDA approvals and tentative approvals for Bpi
This section lists recent FDA approvals and tentative approvals for Lupin, covering innovator and generic drugs with key regulatory details and timelines.
Generic drugs
Includes generic drug submissions with tentative FDA approvals, not yet marketable due to patent or exclusivity restrictions.
| Drug Name | Submission class (FDA) | Submission Category | Submission Date |
|---|---|---|---|
| Selenious Acid |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | - | 07 Jan, 2026 |
| Cabazitaxel |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | - | 22 Mar, 2023 |
Bpi Drug List
Given below is the complete list of Bpi's drugs and the patents protecting them.
1. Epinephrine
Epinephrine is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9283197 | More potent and less toxic formulations of epinephrine and methods of medical use |
15 Aug, 2034
(8 years from now)
| Active |
| US10004700 | More potent and less toxic formulations of epinephrine and methods of medical use |
14 Aug, 2034
(8 years from now)
| Active |
| US10039728 | More potent and less toxic formulations of epinephrine and methods of medical use |
14 Aug, 2034
(8 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Epinephrine's drug page